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ABSTRACT
Non-steroidal anti-inflammatory drugs
(NSAIDs) are a chemically diverse class of
drugs that target the cyclooxygenase (COX)
pathway and have anti-inflammatory,
analgesic, and antipyretic properties. Elevated
expression of COX-2 has been associated with
tumor progression in skin cancer through
multiple mechanisms. We present evidence
for a chemoprotective effect of NSAIDs and
discuss potential mechanisms of action of
COX-2 in cancer. We also discuss the
challenges associated with the treatment of
actinic keratosis and the factors that should be
taken into consideration when selecting a
treatment regimen. A range of treatments are
reviewed, with an emphasis on combination
therapies.
Keywords: Actinic keratosis; Cancer
prevention; Cyclooxygenase; Non-steroidal
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INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs),
a chemically diverse class of drugs with
anti-inflammatory, analgesic, and antipyretic
properties, target the cyclooxygenase (COX)
pathway [1]. Two major isoforms of COX exist:
COX-1 and COX-2 [2]. While both catalyze an
identical enzymatic reaction, the two are
independent and are implicated in distinct
physiologic and pathogenic processes, and they
differ in their pattern of expression: COX-1 is
constitutively expressed in most tissues [3],
whereas COX-2 is usually induced by numerous
physiologic stimuli [4]. COX-1 and COX-2 are
involved in the synthesis of prostaglandins
(PGs), catalyzing the conversion of arachidonic
acid to PGH2. PGH2 is subsequently converted
to a number of eicosanoids, including PGD2,
PGE2, PGF2a, PGI2, and thromboxane (TX).
Both COX-1 and COX-2 are capable of
synthesizing PGs from arachidonic acid.
However, it has been shown that PGE2 and
PGI2 are mainly derived from the COX-2
pathway [5]. The variety of PGs produced
depends on the downstream enzymatic
machinery present in a particular cell type. For
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example, platelets predominantly produce
TXA2.
COX-2 AND SKIN CANCER
Elevated expression of COX-2 occurs in many
cancers, where it contributes to tumor
progression through multiple mechanisms
[6, 7]. There is strong evidence from
epidemiologic studies and animal models that
COX-2 is involved in the development and
progression of cutaneous squamous cell
carcinoma (SCC) and may represent a target
for prevention and/or therapy [8–11].
COX-2 expression is upregulated in human
and murine SCC, accompanied by a high
level of PG synthesis [6]. Genetic and
pharmacologic approaches have been used
to demonstrate the contribution of COX and
PGs to murine skin cancer: COX-2 knockout
mice are significantly protected from
UV-induced skin cancer compared with
wild-type mice [8]. Conversely, transgenic
mice overexpressing COX-2 in the epidermis
develop many more tumors in response to UV
treatment compared with wild-type mice [8].
UV-induced COX-2 expression increases PGE2
production, and overexpression of the PGE2
receptors EP1, 2, and 4 is also associated with
increased numbers of UV-induced tumors
[12–14]. Selective COX-2 inhibitors have
been shown to suppress UV- and
carcinogen-induced SCC [10, 11, 15]. For
example, application of celecoxib has been
shown to reduce UV-associated skin damage
in mice and the number and size of new skin
tumors [10]. The nonselective NSAIDs
naproxen, aspirin, and sulindac have also
been found to significantly reduce the
number of UV-induced skin tumors [2].
While COX-1 and COX-2 are present in
non-melanoma skin cancer in humans [9],
COX-2 is the primary UV-responsive COX
isoform in human skin. UV radiation is a
known stimulus for COX-2 expression in the
epidermis, and single doses of UV (1–2 minimal
erythema dose) results in a substantial increase
in COX-2 expression, with no change in COX-1
expression [16]. While COX-2 is not
detectable in normal skin, it is upregulated in
SCC and actinic keratosis (AK) [17].
Epidemiologic evidence supports a
preventive effect for NSAIDs in the
development of SCC. An Australian
case-control study on a cohort of 1621
individuals found that people who used
NSAIDs twice a week or more for at least a
year had a significantly lower incidence of AKs
and SCCs than those who did not [18]. A Danish
population-based case-control study also found
a decreased risk of developing SCC and
malignant melanoma in individuals taking
NSAIDs, especially with long-term (C7 years)
or high-intensity use ([25% of prescription
coverage during total duration of use) [19].
Although several studies have not found a
significant association between NSAIDs and
SCC protection [20, 21], a recent meta-analysis
of published studies revealed that aspirin and
other oral NSAIDs are associated with a
significant reduction in the risk of SCC
compared with non-use of NSAIDs, and this
association is particularly evident among
individuals with a history of AK or SCC
(Fig. 1). The analysis was not able to determine
whether the dose or duration of NSAID
administration impacted on SCC prevention
[22]. A meta-analysis of topical NSAID
treatment of AKs with the COX-2 inhibitor
diclofenac in 2.5% hyaluronic acid found that
target lesions were completely resolved in 40%
of cases after a mean 75 days of treatment [23].
There is evidence indicating that diclofenac,
which has been approved for the treatment of
AK in the form of diclofenac/hyaluronic acid,
acts by inducing cell death. Topic treatment of
four SCC cell lines (acting as a model for AK
because of a general lack of AK cell lines) with
diclofenac/hyaluronic acid was found to induce
apoptosis, possibly by sensitizing neoplastic
keratinocytes to death ligand-induced
apoptosis [24].
THE MECHANISM OF ACTION
OF COX-2 IN MALIGNANCY
The mechanism by which COX-2 promotes
SCC development is unclear; however, the
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enzyme has been shown to promote several
functions associated with malignant
transformation and progression. PGE2
stimulates the proliferation of keratinocytes
[10], and this effect can be suppressed by
NSAIDs, which also act to promote
keratinocyte apoptosis. COX-2 expression
in SCC has also been shown to correlate
with epithelial-to-mesenchymal transition,
suggesting that COX-2 may promote cell
motility. Consistent with this, COX-2 has
been associated with invasion in squamous
carcinomas of the head, neck, and esophagus
[25, 26]. While PGE2 is involved in the
inflammatory process, paradoxically, it also
has an immunosuppressive role [27]. The
COX-2/PGE2/EP pathway can suppress
activity of dendritic cells, NK cells, and
T-lymphocytes and promote tumor immune
evasion [28]. Zelenay and colleagues recently
demonstrated a synergistic effect between
COX inhibitors and immune checkpoint
inhibitors in a murine cancer model,
suggesting that NSAIDs may have utility as
an immunotherapeutic adjunct [29].
When Should Actinic Keratosis be
Treated?
The decision to treat a patient with AK lesions is
made on the basis of clinical factors, such as a
history of AK lesion persistence, the age of the
patient, presence of discomfort, the extent of
co-existing photodamage, expected tolerance to
the side effects of therapy, and history of skin
cancer [30].
Further support for the decision to treat AK
lesions comes from the finding that similar
genes are differentially expressed in AK and
SCC, confirming that AK is a precursor lesion of
SCC [31]. Elucidation of the process by which
SCC develops from AK has revealed that the
classical progression from AK I to II to III, and
subsequently SCC, occurs in a substantial
proportion of cases, while the direct
progression from AK I to SCC (the so-called
differentiated pathway) is also common [32].
(See ‘Skin cancer—Epidemiology, Disease Burden,
Pathophysiology, Diagnosis and Therapeutic
Approaches,’ by Zoe Apalla, Dorothe´e Nashan,
Richard Weller, and Xavier Castellsague´,
Fig. 1 Forest plot of the association between NSAID (any
aspirin or non-aspirin NSAID) use and SCC development
[22]. Reprinted from J Invest Dermatol, 135, Muranushi
C et al., Aspirin and nonsteroidal anti-inﬂammatory
drugs can prevent cutaneous squamous cell carcinoma: a
systematic review and meta-analysis, 975–83, Copyright
2015, with permission from Elsevier. CI conﬁdence
interval, NSAID non-steroidal anti-inﬂammatory drug,
SCC squamous cell carcinoma
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There are increasing numbers of treatment
options for AK and, correspondingly, a greater
choice for patients. However, the range of
available options can be limited by healthcare
costs and/or reimbursement complications, in
addition to the preferences of the physician
(and patient) for procedural, topic, or
combination treatment. Consequently,
delivering the most appropriate therapy may
be a challenge. Given the scope of the current
article, we summarize below those treatment
options that are applicable to the European
market.
Selecting the most appropriate treatment
should take into account the clinical
presentation of AK: the type, distribution, and
location of lesions and whether field or lesional
treatment is necessary. Also, data on the efficacy
and tolerability of treatments, patient
preference, and cost-effectiveness (prescriber
preference and price) should be considered.
Several evidence-based treatment guidelines
are available to assist clinicians in navigating
the field, including those from the Primary Care
Dermatology Society (Fig. 2).
Physically Destructive Methods
Lesion- or field-directed treatment options
aimed at physically destroying AK lesions
include cryotherapy and laser treatment.
Cryotherapy is non-specific and uses liquid
nitrogen to freeze and promote necrosis of
lesions, although both atypical and normal
cells are at risk of destruction. It is widely used
for small, or a low number of, AK lesions
[33–35]. A single application of cryotherapy
may be sufficient, or treatment can be repeated
several times [35]. Laser (either CO2 or Er:YAG)
treatment destroys skin to a controlled depth
[34]. It is useful when there is co-existent
photodamage or where lesions are recalcitrant,
although hypopigmentation may be a problem
[36].
Surgical Removal
Surgical removal of AK lesions involves excision
or curettage and is suitable for single, discrete,
hyperkeratotic lesions [35]. Surgery is unlikely
to be the first line of treatment, unless diagnosis
is uncertain [34]. While there are no clinical
trials evaluating the efficacy of surgery for AK
lesions, it is likely to be effective [34].
Topical Treatments
A number of topical treatments are available for
the treatment of AK lesions. Diclofenac 3% in
hyaluronic acid [37] is administered twice daily
for 60–90 days for the treatment of AK lesions in
all body areas. Although themechanismof action
of diclofenac inAK isnot known, itmaybe related
to the inhibition of the cyclooxygenase pathway
leading to reduced PGE2 synthesis. Common side
effects include usually mild erythema, crusting,
scaling, and pruritus.
5-Fluorouracil 5% is a chemotherapeutic
agent that destroys tumor cells via blocking
the methylation reaction of deoxyuridylic acid
to thymidylic acid. Treatment is administered
once or twice daily for 3–4 weeks, and a normal
response is associated with an early and severe
inflammatory phase (usually week 2), followed
by a necrotic phase and then healing. Other
common side effects include erythema,
crusting, and pigmentation changes [38].
5-Fluorouracil 0.5% plus 10% salicylic acid
(5-FU/SA) comprises an antimetabolite combined
with a keratolytic agent to reduce hyperkeratoses.
This is administered once daily for 6–12 weeks for
slightly palpable and/or moderately thick
hyperkeratotic AK (grade I/II) lesions on the face,
forehead, or balding scalp (epidermal thickness
must be considered when administering to other
sites). Common side effects of 5-FU/SA include
erythema, inflammation, irritation, pain, and
pruritus [39–41].
Imiquimod 5%, a Toll-like receptor 7
agonist, disrupts tumor proliferation and
induces cytokines with indirect anti-tumor
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effects. It is applied three times per week for
4 weeks on typic, non-hyperkeratotic,
non-hypertrophic AK lesions on the
face/scalp; this is done prior to normal
sleeping hours and washed off after
approximately 8 h. In Europe, this treatment
cycle can be repeated after 4 weeks if required
[42]. Common side effects include erythema,
crusting, and scaling (treatment can be
interrupted if intense local inflammatory
reactions occur). Flu-like symptoms including
headaches, fever, and chills may also be
experienced. Imiquimod 3.75% is applied
once daily for 2 weeks for AK lesions on the
face/scalp (Europe). This is followed by a
2-week break without treatment and then a
further 2 weeks with treatment [43].
Ingenol mebutate was isolated from
Euphorbia peplus and is involved in rapid
targeted cell necrosis and an immune
response. It is applied on non-hyperkeratotic,
non-hypertrophic AK lesions to the
trunk/extremities (500 lg gel) once daily for
2 days and to the face/scalp (150 lg gel) once
daily for 3 days. Erythema, flaking/scaling, and
crusting typically occur within 1 day of
initiation and peak in intensity up to 1 week
following completion of treatment [44, 45].
Conventional methyl aminolevulinate-
photodynamic therapy (MAL-PDT) is
administered to thin or non-hyperkeratotic
and non-pigmented AK lesions on the
face/scalp. After topical application of methyl
aminolevulinate, porphyrins accumulate
intracellularly [including protoporphyrin IX
(PpIX) as photoactive, fluorescing
compounds]; light activation leads to a
photochemical reaction and thereby
phototoxicity to the light-exposed target cells.
During light exposure, common side effects
include burning/stinging pain, whereas
post-therapy swelling and erythema are often
followed by crusting [46]. Conventional
aminolevulinic acid-photodynamic therapy
(ALA-PDT), involving the application of
5-aminolevulinic acid, is administered to
patients with mild-to-moderate AK lesions on
the face/scalp (Olsen grade I–II; refer to Fig. 2)
[47–49]. For conventional ALA-PDT, common
side effects are similar to those observed with
conventional MAL-PDT. Daylight MAL-PDT
[46, 50, 51] may be used to treat patients with
mild-to-moderate AK lesions and is suitable for
most weather conditions (avoiding rainy days)
above 10C. Pain is a common side effect but
minimal compared with standard PDT.
Fig. 2 Primary Care Dermatology Society treatment
guidelines (2014) for actinic keratosis [61]. Reproduced
with kind permission from the Primary Care Dermatology
Society. Treatment recommendations of national
dermatology societies and associations may differ from
those suggested by the Primary Care Dermatology Society
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Combination Therapy
Field therapies have often been combined (or
used sequentially) with each other or with
lesion-targeted therapies in an effort to
improve results by taking advantage of the
synergy of the individual mechanisms of
action [35]. There is increasing interest in the
use of combination or sequential therapy in an
effort to improve outcomes.
In a small studyofpatientswithmultiple grade
I/II AK lesions (including recurrence), diclofenac
in hyaluronic acid was administered twice daily
for 12 weeks, followed by a 2-week treatment-free
interval, and then5-fluorouracil (5-FU)? salicylic
acid once daily for up to 6 weeks, as required.
Complete clinical and histologic clearance
occurred in 83.3% of 12 patients [52].
The combination of diclofenac/hyaluronic
acid therapy with cryotherapy, using different
freeze times and order of therapy, resulted in
higher lesion clearance rates than single-agent
therapy [53–55].
An enhanced clinical effect was observed
when AK lesions were pre-treated with
diclofenac/hyaluronic acid or 5-FU before
photodynamic therapy (PDT), sequential PDT
and imiquimod, with patients having fewer
lesions at follow-up compared with those who
were not pre-treated [56–58]. The combination
of PDT with other treatments, such as
diclofenac/hyaluronic acid, 5-FU, imiquimod,
or ingenol mebutate, appears to improve
outcomes with PDT [59]. However, most of the
studies have included small numbers of
patients, with clinical evaluation only, and no
histologic confirmation of results. Further
studies with larger numbers of patients and
longer follow-up are needed to evaluate these
combinations more fully [59].
ECONOMIC CONSIDERATIONS
In the outpatient setting, AK is among the most
commonly treated skin conditions [33, 60]. As
AK is a disease with increasing incidence, which
may evolve to SCC, the willingness by payers to
cover the cost of AK therapy has increased. As
with all treatments, the National Health Service
and payers will consider clinical data, unmet
needs, the burden of illness, and the
cost-effectiveness and budgetary impact of
potential therapies.
More research is needed on epidemiologic
data, evidence-based standards, delineating
cost drivers in immunocompetent and
immunocompromised patients, and on health
outcomes.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
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